Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors

Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with...

Full description

Bibliographic Details
Main Authors: Christina Darden, Mark Price, David Ray, Grace Goldstein, Diana Goss, Lee Bennett, Diana Garbinsky, Ramya Thota
Format: Article
Language:English
Published: SpringerOpen 2021-09-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Neuroendocrine tumor
Serial survey
Patient experience
Satisfaction
Interviews
Somatostatin analog
Online Access:https://doi.org/10.1186/s41687-021-00355-5

Internet

https://doi.org/10.1186/s41687-021-00355-5

Similar Items